Please provide your email address to receive an email when new articles are posted on . In a phase 2b/3 clinical trial, KSI-301 failed to meet the primary endpoint of noninferior visual acuity gains ...
Kodiak : Study Of KSI-301 On Neovascular Age-related Macular Degeneration Fails To Meet Primary Goal
(RTTNews) - Kodiak Sciences Inc. (KOD) said that phase 2b/3 study of KSI-301 in patients with neovascular (wet) age-related macular degeneration did not meet the primary efficacy endpoint of showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results